Travaux scientifiques

Dr. Uğur Özberk

15 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil
  1. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041657 PMID 41753346 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15135290 PMID 42452749 Texte intégral en libre accèsSource : ORCID

  3. Prognostic Value of the Lung Immune Prognostic Index in Metastatic Renal Cell Carcinoma Treated With Second-Line Immunotherapy

    International journal of urology : official journal of the Japanese Urological Association, 2026

    DOI 10.1111/iju.70619 PMID 42655932 Texte intégral en libre accèsSource : Europe PMC

  4. Machine learning–based prediction of recurrence after curative resection in non–small cell lung cancer

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-47862-3 PMID 41957214 Texte intégral en libre accèsSource : OpenAlex

  5. Prediction of postoperative recurrence in non–small cell lung cancer using machine learning approaches.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e20020 Source : OpenAlex

  6. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16667-y PMID 42693417 Texte intégral en libre accèsSource : OpenAlex

  7. Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15218568 Texte intégral en libre accèsSource : OpenAlex

  8. Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102653 PMID 42700745 Source : OpenAlex

  9. Clinical and microbiological characteristics of abscesses in patients with malignancy and factors associated with 90-day mortality

    Frontiers in Cellular and Infection Microbiology, 2026

    DOI 10.3389/fcimb.2026.1969735 Texte intégral en libre accèsSource : OpenAlex

  10. Machine learning-based prediction of two-year overall survival in metastatic endometrial cancer: a SEER population-based study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-72830-2 Texte intégral en libre accèsSource : ORCID

  11. Elderly Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Therapy and Does Comorbidity Matter

    Medicina, 2025

    DOI 10.3390/medicina61112068 PMID 41303903 Texte intégral en libre accèsSource : ORCID

  12. Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001798 PMID 41430637 1 citation (OpenAlex) Source : OpenAlex

  13. Clinicopathological Features and Treatment Outcomes of Gestational Trophoblastic Disease: A Retrospective Study From A Tertiary Care Center in Türkiye

    Ankara City Hospital Medical Journal, 2025

    DOI 10.5505/achmedj.2025.25633 Texte intégral en libre accèsSource : OpenAlex

  14. A Case of Relapsing Hyponatremia Associated with Fungal Sinusitis

    Case Reports in Nephrology and Dialysis, 2024

    DOI 10.1159/000541579 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  15. A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?

    Transplant Infectious Disease, 2021

    DOI 10.1111/tid.13593 PMID 33655683 9 citations (Europe PMC) Source : ORCID